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CLINICAL SCIENCE
Effects on Anthropometry and Appetite of Vitamins and
Minerals Given in Lipid Nutritional Supplements for
Malnourished HIV-Infected Adults Referred for
Antiretroviral Therapy: Results From the NUSTART
Randomized Controlled Trial
Andrea M. Rehman, PhD,* Susannah Woodd, MSc,* George PrayGod, MD, PhD,†
Molly Chisenga, MSc,‡ Joshua Siame, CO,‡ John R. Koethe, MD,§ Douglas C. Heimburger, MD, MS,§
Paul Kelly, MD,k Henrik Friis, PhD,¶ and Suzanne Filteau, PhD*
Background: The evidence base for effects of nutritional inter-
ventions for malnourished HIV-infected patients starting antiretro-
viral therapy (ART) is limited and inconclusive.
Objective: We hypothesized that both vitamin and mineral deﬁ-
ciencies and poor appetite limit weight gain in malnourished patients
starting ART and that vitamin and mineral supplementation would
improve appetite and permit nutritional recovery.
Design: The randomized controlled Nutritional Support for Africans
Starting Antiretroviral Therapy trial was conducted in Mwanza,
Tanzania, and Lusaka, Zambia. ART-naive adults referred for ART
and with body mass index,18.5 kg/m2 received lipid-based nutritional
supplements either without (LNS) or with added vitamins and minerals
(LNS-VM), beginning before ART initiation. Participants were given
30 g/d LNS from recruitment until 2 weeks after starting ART and 250
g/d from weeks 2 to 6 of ART.
Results: Of 1815 patients recruited, 365 (20%) died during the study
and 813 (45%) provided data at 12 weeks. Controlling for baseline
values, anthropometric measures were consistently higher at 12-week
ART in the LNS-VM than in the LNS group but statistically signiﬁcant
only for calf and mid-upper arm circumferences and triceps skinfold.
Appetite did not differ between groups. Using piecewise mixed-effects
quadratic models including all patients and time points, the main effects
of LNS-VM were seen after starting ART and were signiﬁcant for
weight, body mass index, and mid-upper arm circumference.
Conclusions: Provision of high levels of vitamins and minerals to
patients referred for ART, delivered with substantial macronutrients,
increased nutritional recovery but did not seem to act through
treatment group differences in appetite.
Key Words: nutritional supplementation, anthropometry, body mass
index, antiretroviral therapy, malnutrition
(J Acquir Immune Deﬁc Syndr 2015;68:405–412)
INTRODUCTION
The expanded access to antiretroviral therapy (ART) in
Africa has brought many beneﬁts but leaves challenges.
Malnutrition is a particular concern in patients referred for
ART. Malnourished patients are at high risk of dying in the
early months after starting ART1,2 and failure to gain weight
during this period is an additional mortality risk.3–6 The few
trials of nutritional interventions to reduce these risks have
shown limited beneﬁts.7 In part, this is because many trials
have been conducted in high-income countries where patients
are generally less malnourished, food insecure, and less likely
to be suffering environmental enteropathy8 and malabsorption
than in HIV-endemic sub-Saharan Africa. Another problem
has been an understandable reluctance to have a control group
of malnourished patients without food supplements. A trial in
Malawi compared 2 supplements, corn soy blend and a lipid
nutritional supplement (LNS). The more energy-dense LNS
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resulted in additional early increases in body mass index
(BMI), but this was not sustained and the high early mortality
was not reduced.9,10 A recent trial in Ethiopia used a delayed
intervention control group for patients with BMI .17 kg/m2
and found that an LNS preparation could improve lean mass
gain as well as functional outcomes.11
Another reason for the disappointingly modest beneﬁts
of nutritional interventions is that anorexia is common among
malnourished patients with HIV starting ART12 and weight
regain cannot be expected until appetite improves. Energy
intake was the major driver of weight change in HIV-infected
British adults in the preantiretroviral era,13 and pediatric data
indicate an association between micronutrient supplementa-
tion, appetite, and weight gain in HIV-infected South African
children.14 Protocols for the management of severe malnutri-
tion among young children start with a stabilization phase
with antibiotics, vitamins, and minerals but limited calorie
provision, and only aim for weight regain once appetite has
returned.15 The Nutritional Support for Africans Starting
Antiretroviral Therapy (NUSTART) trial was designed to
mimic this 2-stage nutritional management protocol for
malnourished (BMI ,18.5 kg/m2) African adults starting
ART, with the goals of reducing early mortality and
improving nutritional recovery and functional status. Based
on previous studies demonstrating beneﬁts from both LNS
and vitamin/mineral supplementation, we hypothesized that
a supplement combining both these elements would be
superior to LNS alone. In this analysis, we assess 12-week
changes in anthropometry and appetite among participants
randomized to receive LNS fortiﬁed with additional vitamins
and minerals in a 2-stage protocol from referral for ART until
6 weeks after starting ART compared with those given
control LNS without additional vitamins and minerals.
PARTICIPANTS AND METHODS
Design
The NUSTART study was a phase III individually
randomized controlled trial comparing, in a 2-stage protocol,
vitamin and mineral supplements in LNS (LNS-VM) with
control LNS given from recruitment at referral for ART until
6 weeks after starting ART. The trial was registered as
PACTR201106000300631.
Setting
The study was conducted from August 2011 to
December 2013 at 2 sites: the National Institute for Medical
Research (NIMR), Mwanza, Tanzania and the University
Teaching Hospital (UTH), Lusaka, Zambia. In Mwanza,
patients were screened at 6 peripheral clinics and recruitment
was conducted at a research clinic in Sekou Toure Regional
Hospital. In Lusaka, patients were recruited from 6 peripheral
clinics, which referred to UTH. Approximate HIV prevalence
among adults in Mwanza region is 6%16 and in Lusaka is
21%.17 In both countries, at the time of the study, antire-
troviral drugs were provided free for those with either CD4
lymphocyte count ,350 cells per microliter or WHO stage 3
or 4 disease. About a third of patients starting ART in both
countries have BMI ,18.5 kg/m2.3,5
Participants
Inclusion criteria were at least 18 years old, ART naive
(except for standard regimens to prevent maternal-to-child
HIV transmission), BMI ,18.5 kg/m2, requiring ART as
determined by CD4 count,350 cells per microliter or stage 3
or 4 disease, willing to undertake intensive follow-up in the
study clinic, providing written (or thumbprint if unable to
write) informed consent. In the presence of clinical edema,
patients with BMI ,20 kg/m2 were considered; BMI was
remeasured after loss of edema, and the patient considered
eligible if BMI was ,18.5 kg/m2 and ART had not yet been
initiated. Exclusion criteria were participation in a potentially
conﬂicting research protocol, or pregnancy by self-report.
Intervention
The LNS, made for the trial by Nutriset, Malaunay,
France, and based on the company’s similar products for treating
malnourished children, contained 60% calories as fat and 10%
calories as protein and came in ready-to-eat packets. Within each
treatment arm, the intervention products contained the same
daily amounts of vitamins and minerals in both treatment stages.
LNS-VM contained micronutrients mostly at 3 times the United
Kingdom recommended nutrient intake for adult women,18
except iron at 1 recommended nutrient intake only in the
second stage. Control LNS contained vehicle and ﬂavorings
similar to LNS-VM but no added vitamins or minerals (for
composition of supplements see Table S1, Supplemental Digital
Content, http://links.lww.com/QAI/A611). In the ﬁrst stage,
from recruitment to 2 weeks after starting ART, LNS or LNS-
VM were given with minimal calories, that is, 30 g/d, about
150 kcal/d. From 2 to 6 weeks after initiating ART, LNS or
LNS-VM were given in 250 g/d, in two 125-g sachets, about
1400 kcal/d.
Randomization and Blinding
Randomization was conducted by the Data Safety and
Monitoring Board statistician using computer-generated
blocks of 16 and stratiﬁed by country. Packages of LNS-
VM and LNS, in both small- and large-dose formats, were
labeled with the study ID numbers by the clinic pharmacists
at the time packets were dispensed. Participants were
recruited to sequential IDs (within sites) by clinic nurses
with no access to the code.
Sample Size Justification
The original sample size of 2300 was based on the
primary outcome of mortality between referral for ART and
12 weeks after starting ART, and calculated using data from
Lusaka3 and Cape Town.19 However, mortality was higher
(83/100 person-years) than that used for determining sample
size (25/100 person-years) so, after discussion with the Data
Safety and Monitoring Board, we stopped recruitment in
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July 2013 with a total of 1815 recruits. This number was
sufﬁcient to detect, at 5% signiﬁcance, 90% power, and 25%
attrition by 12 weeks due to death or loss to follow-up,
differences of 0.18 of an SD in secondary continuous
outcomes measured at 12 weeks.
Participant Recruitment and Follow-up
Adults attending free HIV testing services at both sites
who were determined to require ART and fulﬁlled the study
inclusion criteria were eligible for the trial. Before initiating
ART, patients were screened and commenced on treatment
for opportunistic infections and counseled regarding the need
for lifelong drug treatment. During this pre-ART period, of
modal duration 14–20 days in NUSTART, the ﬁrst-stage
study interventions were introduced. Medical care, including
choice of ART regimen, was based on national treatment
guidelines and provided primarily by local health services.
Patients were seen weekly from recruitment until ART
initiation, then at 2, 4, 6, 8, and 12 weeks after starting ART.
Patients who were ill could come for unscheduled visits at any
time. Efforts were made to contact patients not attending
scheduled visits or their families by mobile phone or home visit.
Outcomes
Weight was measured at all visits and height at
recruitment. Detailed anthropometric measures—mid-upper
arm, waist, hip, and calf circumferences, triceps, and
subscapular skinfolds—were made at recruitment, and 2, 6,
and 12 weeks after starting ART. Measurements were taken
in triplicate and the median used in analyses. Arm muscle
area was calculated from mid-upper arm circumference and
triceps skinfold using standard methods.20 Staff conducting
anthropometry were trained according to standard protocols.21
Technical errors of measurement were within acceptable
limits22 for all anthropometric measures in Lusaka and for
all but skinfolds in Mwanza; therefore, only Lusaka results
were used for skinfold analyses.
Appetite was assessed by a 4-question questionnaire (for
questionnaire, see Table S2, Supplemental Digital Content,
http://links.lww.com/QAI/A611); questions were combined into
FIGURE 1. Flow of participants
through the study. Screening in
Mwanza was of all HIV-infected pa-
tients referred for CD4 testing,
whereas in Lusaka, only patients
who also had BMI ,18.5 kg/m2
were formally screened; this resulted
in a greater proportion of ineligible
patients in Mwanza. 1Not meeting
inclusion criteria (n = 2608): 5 ,18
years, 17 non-ART naive, 303 BMI
.18.5 kg/m2, 16 unwilling for
intensive follow-up, 10 pregnant, 4
enrolled in other study, 21 refused
CD4 count, 2222 not eligible for
ART, and 10 unwilling to start ART.
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a single score for each patient at each visit using polychoric
correlation23 with lower scores representing lower appetite.
Previous work from the cohort24 showed that appetite score was
associated with weight change in Mwanza patients but was
unreliable in Lusaka patients; therefore, effects of treatment on
appetite score were analyzed only for Mwanza patients.
Data Management and Statistics
Data were double entered into OpenClinica data man-
agement system in Lusaka and into CSPro 4.1 and stored in
MySQL databases in Mwanza. Analyses were conducted in
STATA version 13.1 (Timberlake Consultants, London, UK)
and SAS version 9.3 (SAS Institute Inc., Cary, NC). Analysis
was by intention to treat. Anthropometric measures and appetite
score (among Mwanza patients only24) 12 weeks after starting
ART were analyzed as continuous variables; mean values were
compared between groups using t tests and linear regression,
adjusting for baseline values. Principal component analysis,25
used to describe socioeconomic status of the population, was
conducted separately for each country since there were notable
differences between sites; variables included in the principal
component analysis were housing characteristics, sanitation,
water source, and ownership of speciﬁc assets.
Results at 12 weeks could be analyzed only for patients
who survived and attended the 12-week visit within our
preplanned 14 days of the scheduled date; however, we also
wished to investigate treatment effects using the detailed
longitudinal data collected on all patients over the course of
the study. We used piecewise mixed-effects quadratic regression
models to allow inclusion of data from patients who died or
were lost to follow-up until the point they were lost from the
study. The additional ﬂexibility of cubic models and cubic
splines was assessed but ﬁt was considered adequate with
quadratic models.26 The time axis was split at the date of starting
ART, allowing 2 lines with differing slopes to be ﬁtted per
person while restricting these lines to join at the date of ART
initiation. For presentation, the marginal predictions after starting
ART were based on the median time, 21 days, spent before
starting ART; predictions pre-ART are not graphed because of
the complexity of showing different lengths of time before ART.
Ethics
Ethical approval was obtained from the London School
of Hygiene and Tropical Medicine, the University of Zambia
Research Ethics Committee, and the Medical Research
Coordinating Committee of NIMR, Tanzania. All participants
provided written or thumbprint informed consent. Medical
care of patients was according to national guidelines and
provided through the local health services.
RESULTS
Figure 1 shows the ﬂow of participants through the
study, including numbers with results at key time points.
Table 1 describes the full population at recruitment and shows
balance between treatment arms. Edema was uncommon at
baseline and all patients with edema had BMI,18.5 kg/m2 at
TABLE 1. Baseline Characteristics of the Study Population
Variable Level LNS-VM LNS
N (%) 914 (50.4) 901 (49.6)
Age, mean (SD), yrs 35.9 (9.4) 35.7 (9.4)
Female, n (%) 443 (49) 457 (51)
BMI, mean (SD), kg/m2 16.4 (1.4) 16.4 (1.4)
BMI ,17, n (%), kg/m2 542 (59) 532 (59)
CD4 count, mean (SD), cells/mL 134 (97) 139 (103)
CD4 count group n (%), cells/mL ,50 227 (25) 216 (24)
50–99 171 (19) 176 (20)
100–199 279 (31) 252 (28)
$200 237 (26) 257 (29)
Hemoglobin, mean (SD), g/L 95 (23) 97 (24)
Hemoglobin group*, n (%) Severe anemia 207 (23) 191 (21)
Moderate anemia 422 (46) 388 (43)
Mild anemia 128 (14) 157 (17)
Normal 82 (9) 95 (11)
Missing 75 (8) 70 (8)
Phosphate ,0.87 mmol/L, n (%) ,0.87 113 (12) 83 (9)
Missing 26 (3) 25 (3)
Marital status, n (%) Married/Cohabiting 420 (46) 438 (49)
Widowed 96 (11) 107 (12)
Divorced-separated 266 (29) 244 (27)
Single 132 (14) 111 (12)
Missing 0 (0) 1 (0.1)
Occupation, n (%) Salaried 134 (15) 137 (15)
Self-employed 485 (53) 460 (51)
Housewife 86 (9) 97 (11)
Student 9 (1) 9 (1)
Unemployed 200 (22) 197 (22)
Missing 0 (0) 1 (0.1)
Education, n (%) None 170 (19) 173 (19)
Primary 528 (58) 517 (57)
Secondary 192 (21) 185 (21)
Tertiary 24 (3) 25 (3)
Missing 0 (0) 1 (0.1)
Socioeconomic quintiles†,
n (%)
Lowest 166 (18) 198 (22)
Low 185 (20) 189 (21)
Middle 200 (22) 162 (18)
High 173 (19) 182 (20)
Highest 190 (21) 170 (19)
TB treatment pre-ART, n (%) 252 (28) 199 (22)
Edema at baseline, n (%) 31 (3) 35 (4)
Initial ART regimen, n (%) AZT/3TC/EFV 68 (10) 67 (9)
AZT/STC/NVP 111 (16) 125 (17)
TDF/FTC/EFV 418 (58) 398 (55)
TDF/FTC/NVP 31 (4) 33 (5)
Other 30 (4) 24 (3)
Missing 59 (8) 71 (10)
*Hemoglobin categories were selected based on usual nutritional cutoffs, not as
deﬁned for speciﬁc adverse events; adequate hemoglobin was deﬁned as 130 g/L for
men and 120 g/L for women; mild anemia was 110 g/L to the adequate cutoff; moderate
anemia was 80–109 g/L; severe anemia was ,80 g/L.
†Socioeconomic quintiles analyzed for each site separately by PCA.
3TC, lamivudine; AZT, zidovudine; CI, conﬁdence interval; EFV, efaviranz; FTC,
emtricitabine; NVP, nevirapine; PCA, principal component analysis; TB, tuberculosis;
TDF, tenofovir.
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recruitment. Patients who died before 12-week ART were
more likely to be male, had lower values for anthropometric
measures, hemoglobin, and CD4 count, poorer appetite, and
were less likely to be on treatment for tuberculosis and more
likely to have edema at recruitment than those providing data
at 12 weeks of ART (for detailed baseline data of participants
included at 12 weeks, dead by 12 weeks, and not attending
the 12-week visit, see Table S3, Supplemental Digital
Content, http://links.lww.com/QAI/A611). Those not known
to be dead but who missed the 12-week visit were younger
than those who did attend the 12-week visit, had slightly
poorer nutritional status, and were more likely to be in the
lowest socioeconomic quintile.
All anthropometric measures at 12 weeks showed
a tendency toward higher values in the LNS-VM group
(Table 2). Controlling for baseline values, the differences
were signiﬁcant for mid-upper arm and calf circumferences
and triceps skinfold. Appetite at 12 weeks did not differ
between groups.
Figure 2 presents regression curves for changes in BMI
and appetite score after starting ART; similar curves for other
anthropometric markers are in Figure S1 (see digital content for
curves of other anthropometry after starting ART; see Supple-
mental Digital Content, http://links.lww.com/QAI/A611).
Table 3 shows the associated P values for regressions both
pre-ART and during ART. There was very little change in
any measure before starting ART; there were also no pre-
ART differences between treatment groups (Table 3).
Appetite score, in contrast, was higher at initiation of
ART than at recruitment but did not differ between
treatment groups. All anthropometric measures and appe-
tite increased greatly after the start of ART. Increases
tended to be greater in the LNS-VM group but differences
during ART were signiﬁcant for only weight, BMI, and
mid-upper arm circumference. The longitudinal analyses
were repeated after restricting the cohort to only those
patients with 12-week data, that is, those in Table 2, to
determine whether the inclusion of patients who died
TABLE 2. Effects of Treatment on Anthropometry and Appetite at 12 Weeks After Starting ART
n
Mean at 12-wk ART
(SD)
Difference in 12-wk Mean Values
(95% CI) P
Adjusted Difference in Mean Values*
(95% CI) P
Weight, kg 421 50.2 (0.3) 0.71 (20.22 to 1.64) 0.14 0.47 (20.15 to 1.08) 0.14
LNS-VM
LNS 392 49.5 (0.3)
BMI, kg/m2 421 18.5 (0.1) 0.15 (20.10 to 0.41) 0.23 0.15 (20.08 to 0.37) 0.20
LNS-VM
LNS 392 18.4 (0.1)
Mid-upper arm
circumference, cm
407 23.8 (0.1) 0.38 (0.07 to 0.69) 0.02 0.39 (0.12 to 0.65) 0.004
LNS-VM
LNS 375 23.4 (0.1)
Waist circumference, cm 408 71.9 (0.3) 0.18 (20.58 to 0.94) 0.64 0.56 (20.09 to 1.20) 0.09
LNS-VM
LNS 376 71.7 (0.3)
Hip circumference, cm 407 84.1 (0.3) 0.15 (20.55 to 0.85) 0.68 0.19 (20.39 to 0.77) 0.52
LNS-VM
LNS 376 84.0 (0.3)
Calf circumference, cm 408 30.3 (0.1) 0.33 (0.002 to 0.65) 0.05 0.27 (0.01 to 0.52) 0.04
LNS-VM
LNS 376 29.9 (0.1)
Triceps skinfold†, mm 265 8.6 (0.2) 0.50 (20.10 to 1.10) 0.10 0.46 (0.03 to 0.90) 0.04
LNS-VM
LNS 233 8.1 (0.2)
Subscapular skinfold†, mm 266 8.3 (0.1) 0.11 (20.29 to 0.50) 0.60 0.10 (20.20 to 0.41) 0.51
LNS-VM
LNS 233 8.2 (0.1)
Mid-arm muscle area†, cm2 265 35.7 (6.7) 0.6 (20.6 to 1.7) 0.33 0.7 (20.3 to 1.7) 0.18
LNS-VM
LNS 233 35.1 (6.5)
Appetite score‡ 152 1.00 (0.99) 20.05 (20.29 to 0.18) 0.65 20.10 (20.32 to 0.12) 0.39
LNS-VM
LNS 153 1.05 (1.08)
*Adjusted for baseline value.
†Only Lusaka data used.
‡Only Mwanza data used.
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accounted for differences in the results, but this did not
seem to be the case (data not shown).
DISCUSSION
Malnutrition and failure to increase weight are estab-
lished risk factors for early mortality in patients starting ART
and interventions to date to decrease these risks have had
limited success. The NUSTART trial randomized intervention
had no effect on mortality,27 but the present results demon-
strate beneﬁts for anthropometry. All point estimates at 12-
week ART were higher in the LNS-VM group, but differ-
ences were not all statistically signiﬁcant, and since some
were small, possibly not biologically signiﬁcant. The border-
line nature of the group differences likely explains why some
were statistically signiﬁcant in the 12-week analyses and
others in the longitudinal analyses using the full cohort. There
are several possible reasons for the modest treatment group
differences. First, since all patients were malnourished and we
considered a no supplement control would have been
unethical, our control group received macronutrients as well
as modest amounts of micronutrients contained within the
LNS preparation. This, plus the ART and other medical care,
resulted in rapid anthropometric gains in both treatment
groups and may have made differences between groups
difﬁcult to detect. Signiﬁcant effects on anthropometry were
FIGURE 2. Comparisons between treatment
groups of BMI and appetite score after starting
ART. Curves represent predictions based on all
available data for all patients and are derived from
quadratic equations with random slopes and in-
tercepts, assuming the median pre-ART period of
21 days.
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seen in the Ethiopian trial, which used a delayed intervention
control which received no food supplement during the ﬁrst 3
months of ART.11 Second, we aimed for a short intervention
period, which could be potentially scaled up at reasonable
cost, but it is possible that the period was not long enough for
provision of vitamins and minerals with calories to make
a difference to anthropometry at 12 weeks, that is, 6 weeks
after ending supplementation, compared with calories alone.
Third, the ongoing inﬂammation in the NUSTART patients,
as assessed by plasma C-reactive protein 6 weeks after
starting ART (PrayGod et al., submitted), may have acted
as a driver of tissue catabolism, rather than of deposition,
through much of the NUSTART trial period.
Comparisons at 12 weeks after starting ART would
miss changes earlier in the study, so the longitudinal analyses
were conducted to capture these. It is interesting that both
increases in anthropometric outcomes and differences
between treatment groups were minimal before ART but
larger after starting ART and after starting the higher calorie
supplement at 2 weeks of ART. It is difﬁcult from the
NUSTART study design to distinguish effects due to pro-
viding ART and providing higher calories. We noted pre-
viously that starting ART dampened increases in appetite
among the patients for a period of several weeks24; neverthe-
less, appetite seemed sufﬁcient to lead to increases in
anthropometry from the start of ART.
A central concept in the design of the NUSTART trial
preparations was that the micronutrients and electrolytes would
improve lean tissue deposition.28 The results show all anthro-
pometric measures increasing in both groups but slightly more
in the LNS-VM group. Anthropometry measures both fat and
lean and our only measure related speciﬁcally to lean tissue,
arm muscle area, did not differ between treatment groups;
however, more sophisticated body composition data are needed
to determine whether there is preferential fat or lean deposition.
Our appetite results are limited by having valid data from only
1 site and perhaps by being insufﬁciently sensitive; neverthe-
less, if it really is true that additional vitamins and minerals can
increase body mass in various compartments without an overall
difference between groups in appetite or intake, this implies an
increase in efﬁciency of anabolic processes. Increased efﬁ-
ciency is exactly what would be expected if availability of
coenzymes and cofactors were rate limiting in tissue accretion
during nutritional rehabilitation. This intriguing possibility
requires further work as it is of the greatest importance in
understanding how best to deliver nutritional therapy.
The study had several limitations, which together
decreased statistical power. Trial recruitment was stopped
earlier than originally planned, based on requirements for the
primary outcome of mortality. Furthermore, a large pro-
portion of recruits did not attend the ﬁnal visit due to either
death or loss to follow-up. However, we still had power to
detect differences in anthropometric measures of about 0.2 of
an SD score, which is about the limit of biologically relevant
differences. Because of technical problems, we could not use
the skinfold data from Mwanza; however, we could still
detect a signiﬁcant effect of treatment on triceps skinfold
thickness in Lusaka patients at 12 weeks.
In conclusion, the NUSTART intervention improved
nutritional outcomes in both groups of malnourished patients
starting ART; high levels of vitamins and minerals had
additional beneﬁts. Together with the results from Malawi10
and Ethiopia,11 the NUSTART trial supports use of LNS for
these patients.
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